Cargando…
Benefit–risk evaluation: the past, present and future
In the last two decades there has been a shift in the approach to evaluating the benefit–risk (BR) profiles of medicinal products from an unstructured, subjective, and inconsistent, to a more structured and objective, process. This article describes that shift from a historical perspective; the past...
Autor principal: | Juhaeri, Juhaeri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712756/ https://www.ncbi.nlm.nih.gov/pubmed/31489173 http://dx.doi.org/10.1177/2042098619871180 |
Ejemplares similares
-
Structured benefit–risk evaluation for medicinal products: review of quantitative benefit–risk assessment findings in the literature
por: Kürzinger, Marie-Laure, et al.
Publicado: (2020) -
Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study
por: Johnson, Eric S, et al.
Publicado: (2011) -
Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance
por: Bate, Andrew, et al.
Publicado: (2019) -
Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics
por: Tave, Arlene, et al.
Publicado: (2021) -
Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison
por: Whichello, Chiara, et al.
Publicado: (2020)